Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Plans Senior Note Offering

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific plans to offer its 2.5 percent senior convertible notes in an effort to raise funding to refinance some of its outstanding debts, the company said today.

The life sciences and biotech firm intends to offer the 2.5 percent senior notes, due 2023, of which $295.4 million aggregate principal amount is outstanding as of November 12, 2009, in a private placement to qualified institutional investors.

The company also plans to redeem its 6.75 percent senior subordinated notes due 2014, of which $300 million in aggregate principal is outstanding.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.